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Background: Kinases represent potential therapeutic targets in pancreatic endocrine tumours (PETs).
Patients and methods: Thirty-ﬁve kinase genes were sequenced in 36 primary PETs and three PET cell lines: (i) 4
receptor tyrosine kinases (RTK), epithelial growth factor receptor (EGFR), human epidermal growth factor receptor 2
(HER2), tyrosine-protein kinase KIT (KIT), platelet-derived growth factor receptor alpha (PDGFRalpha); (ii) 6 belonging
to the Akt/mTOR pathway; and (iii) 25 frequently mutated in cancers. The immunohistochemical expression of the four
RTKs and the copy number of EGFR and HER2 were assessed in 140 PETs.
Results: Somatic mutations were found in KIT in one and ATM in two primary neoplasms. Among 140 PETs, EGFR
was immunopositive in 18 (13%), HER2 in 3 (2%), KIT in 16 (11%), and PDGFRalpha in 135 (96%). HER2 ampliﬁcation
was found in 2/130 (1.5%) PETs. KIT membrane immunostaining was signiﬁcantly associated with tumour
aggressiveness and shorter patient survival. PET cell lines QGP1, CM and BON harboured mutations in FGFR3, FLT1/
VEGFR1 and PIK3CA, respectively.
Conclusions: Only rare PET cases, harbouring either HER2 ampliﬁcation or KIT mutation, might beneﬁt from
targeted drugs. KIT membrane expression deserves further attention as a prognostic marker. ATM mutation is
involved in a proportion of PET. The ﬁnding of speciﬁc mutations in PET cell lines renders these models useful for
preclinical studies involving pathway-speciﬁc therapies.
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introduction
Pancreatic endocrine tumours (PETs) arise sporadically or as
part of hereditary cancer syndromes including multiple
endocrine neoplasia type 1 (MEN1) [1, 2]. Indeed, MEN1
alterations in the gene sequence and/or protein expression
remain the only consistent change also found in the sporadic
form of the disease [3]. According to the World Health
Organisation classiﬁcation, PETs are divided into well-
differentiated endocrine tumours and carcinomas or poorly
differentiated endocrine carcinomas [4]. Surgery should be
considered for all patients as ﬁrst-line treatment offering
a chance for cure even in a proportion of malignant PETs [5].
However, only few effective chemotherapic agents are available
to date for the treatment of advanced stage disease. Moreover,
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growing tumours, which show resistance to conventional
cytotoxic agents. Therefore, the identiﬁcation of new
therapeutic strategies represents the main challenge for these
neoplasms. In this scenario, protein kinases stand out as
potential therapeutic targets to be investigated in PETs [6–8].
Protein kinases are key components of signalling pathways
involved in the regulation of different and complex cellular
processes such as cell cycle progression, differentiation,
apoptosis and invasion [9, 10]. The protein kinase complement
(deﬁned as ‘kinome’) represents a signiﬁcant fraction of the
human genome, and recently Manning et al. [11] organised it
into a dendogram containing nine broad groups of genes.
Alterations in a kinase gene, such as point mutations and
deletions in conserved domains, can lead to a constitutively
activated kinase, that is a potential target for cancer treatment
or to its inactivation, as for genes involved in the maintenance
of genome stability [12]. Regarding PETs, the importance of
Akt-mTOR pathway and its therapeutic relevance has been
largely investigated but no deﬁnite data about the mutational
proﬁle of the individual kinase components of this pathway in
PETs is available to date [13–17].
Lately, extensive sequence analysis of kinase tumour
genomes has been conducted in different epithelial tumours
[18–21]. These works point out a subset of kinases with
known or potential relationship with solid tumour
development as they display a relatively high frequency of
somatic mutations.
The rationale for the targeting of kinases resides not only
in the identiﬁcation of potentially activating mutations at
the gene level but also in the determination of the expression
of the corresponding mutant proteins in tumour tissues. This
is particularly important when targeting receptor tyrosine
kinases (RTKs) with the use of monoclonal antibodies or
inhibitors of their tyrosine kinase activity [22–26]. About the
presence and role of protein kinases, particularly of RTKs, in
PETs, inconsistent results have been reported [27–35].
In the present study, we explored the kinome searching
a panel of 36 primary PETs and 3 PET cell lines for mutations
in 35 kinase genes including: 25 genes frequently mutated in
human cancers other than pancreatic [18–21], 6 genes related
to the Akt-mTOR pathway that has been shown to be activated
in PET [17], and 4 genes encoding for RTKs targeted by
available anticancer drugs. For these latter, the protein
expression by immunohistochemistry and gene copy number
status by ﬂuorescence in situ hybridisation (FISH) was assessed
in a large series of 140 primary PETs.
materials and methods
mutational analysis
samples. The panel of 36 primary PETs was collected according to the
ethical requirements of the review board of the University of Verona
(supplemental Table S1 is available at Annals of Oncology online). No
patient underwent neoadjuvant therapy. Three PET cell lines, QGP1, BON
and CM, were included in the study [36, 37]. Samples containing >80%
tumour cells were used. Genomic DNA was isolated using DNAesy Blood
and Tissue Kit (Qiagen, Milan, Italy). Matched normal DNA served to
determine the somatic or germline nature of mutations.
sequencing and data analysis. The panel of 35 kinase genes selected for
mutational analysis is listed in supplemental Table S2 (available at Annals of
Oncology online). Primers for ampliﬁcation and sequencing were designed
using Primer3 program (http://frodo.wi.mit.edu/cgi-bin/primer3/
primer3_www.cgi) and refer to National Centre for Biotechnology
Information (NCBI; http://www.ncbi.nlm.nih.gov). PCR primers were
designed to amplify the selected exons and the ﬂanking intronic sequences,
including splicing donor and acceptor regions. PCR products were 400 bp
in length, with multiple overlapping amplimers for larger exons. PCR and
direct sequencing conditions were described [38]. Sequence differences to
the NCBI reference sequence were identiﬁed via manual inspection of
aligned electropherograms assisted by the Mutation Surveyor software
package (SoftGenetics, State College, PA). The genetic alterations identiﬁed
were cross-referenced to variant information from international databases
(NCBI SNP database, The Swiss-Prot and GenBank databases, and the
COSMIC database) and literature. In addition to nonsynonymous genetic
alterations, we detected numerous silent sequence variations that are not
presented and further analysed here.
immunohistochemistry and ﬂuorescence in situ
hybridisation
tissue microarrays. Parafﬁn-embedded tissue microarrays (TMAs)
contained 140 primary PETs, 38 matched metastasis (22 nodal and 16 liver)
and 12 normal pancreas. No patient underwent neoadjuvant therapy. The
construction of the TMAs was carried out using a tissue arrayer (Beecher
Instruments, Silver Spring, MD) as previously described [39]. For most
cases, at least three cores of 1 mm diameter per sample were analysed.
Clinicopathological characteristics of PETs are reported in supplemental
Table S3 (available at Annals of Oncology online).
immunohistochemistry. TMAs were immunostained using the antibodies
listed in Table 1. Primary antibodies were omitted in negative controls.
Detection was carried out using Dako EnVision Plus-HRP kit (Dako,
Carpinteria, CA). Slides were scanned with ScanScope
  GL System (Aperio
Technologies, Vista, CA) and visualised using ImageScope
  Software
(Aperio Technologies). To be considered positive, >10% of tumour or
stromal cells had to show positive staining. Three independent observers
scored protein expression. The staining intensity was classiﬁed into four
grades: (0, absent; 1, weak; 2, moderate; 3, strong).
ﬂuorescence in situ hybridisation. FISH was carried out as described [40]
using epithelial growth factor receptor (EGFR) and human epidermal growth
factor receptor 2 (HER2) locus-speciﬁc and chromosomes 7 and 17
centromeric probes (Vysis, Downers Grove, IL) diluted 1 : 100 in tDenHyb1
buffer (Insitus, Albuquerque, MN). The slides were examined using a Zeiss
Axioplan 2 microscope (Zeiss, Gottingen, Germany) and the appropriate ﬁlters.
Table 1. Antibodies used in the immunohistochemical analysis
Antibody Clone/code number Manufacturer
EGFR Clone 2-18C9 Dako (Carpinteria, CA)
a
HER2 Code K5207 Dako
KIT Code A4502 Dako
PDGFRalpha Code 3164 Cell Signaling (Danvers, MA)
EGFR, epidermal growth factor receptor; HER2, human epidermal growth
factor receptor 2; KIT, tyrosine-protein kinase KIT; PDGFRalpha, platelet-
derived growth factor alpha.
aAnti-EGFR antibody is part of the FDA approved DakoCytomation EGFR
pharmDx  kit.
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Association of mutational, immunohistochemical and FISH results with
clinicopathological variables was evaluated using Pearson’s chi-square tests
or Fisher’s test when appropriate for categorical variables; Kruskal–Wallis
test or Wilcoxon test for continuous variables and log-rank tests for time to
progression and survival. Time to progression was considered as the time
between radical surgery and the examination of the patient in which
progression could be detected. In survival analysis, patients dead of causes
other than disease were censored at the time of death. All tests were
considered signiﬁcant when P > 0.05. For all the calculation the R statistical
software package was used (http://www.r-project.org).
results
mutational analysis of 35 kinase genes
All exons of the 35 selected genes were analysed in 36
primary PETs and 3 PET cell lines, with 6240 PCR products,
spanning over 2.5 Mb of tumour genomic DNA, generated
and subjected to direct sequencing. Changes previously
described as single nucleotide polymorphisms (SNPs) were
excluded from further analysis. To ensure that the observed
mutations were not PCR or sequencing artefacts, amplicons
were independently re-ampliﬁed and resequenced. All veriﬁed
changes were resequenced in parallel with matched normal
DNA to distinguish between somatic mutations and SNPs not
previously described. This approach led to the identiﬁcation
of six different nonsynonymous mutations (Table 2). Three
were in primary PETs: two in ATM and one in tyrosine-protein
kinase KIT (KIT). One each in FGF3, FLT1/VEGFR1 and
PIK3CA were identiﬁed in endocrine tumour cell lines.
Two different mutations occurred in ATM (p.R823C and
p.S2017I),acancerrecessivegenesencodingforaserine/threonine
kinase involved in DNA damage response [41]. Germline
mutations of ATM predispose to ataxia telangiectasia and breast
cancer [41, 42]. The mutations found in our two PETs were
somatic as assessed by sequencing of matched normal DNA. The
most interesting mutation is the p.S2017I that occurs in FAT
domain of unknown functional signiﬁcance but highly conserved
between the members of the PIKK (phosphatidylinositol 3-
kinase-related kinase) family, which includes ATR and DNA-PK
[41]. Inactivating mutations of ATM have not been previously
implicated in the development of PETs.
Among the four genes encoding for RTKs targeted by
available anticancer drugs, we report for the ﬁrst time
a nonsense somatic mutation in the kinase domain of KIT
(p.R796stop) in a primary PET, while no mutation was found
in EGFR, HER2 and platelet-derived growth factor receptor
alpha (PDGFRalpha).
No mutation was detected in the six genes belonging to the
Akt/mTOR pathway: AKT2, PIK3CA, RPS6K1, STK11, PDPK1,
FRAP1-mTOR.
immunohistochemical expression of RTKs
Immunohistochemical staining for EGFR, HER2, KIT and
PDGFRalpha was evaluated in TMAs containing 140 primary
PETs and 38 matched metastasis (22 nodal and 16 liver)
(Figure 1). The results are summarised in Table 3.N o
differences in the staining patterns were observed between
primary tumours and matched metastases for all antibodies.
The results of immunohistochemical staining for EGFR,
HER2, KIT and PDGFRalpha, of TMAs containing 140 primary
PETs and 38 matched metastasis (22 nodal and 16 liver) are
summarised in Table 3. Figure 1 shows examples of staining
patterns. No differences in staining patterns were observed
between primaries and matched metastases for all antibodies.
EGFR expression. Of 140 PETs 18 (13%) stained for EGFR with
sharp membranous pattern and signals ranging from very
strong to weak (Figure 1B). Speciﬁcally, 10 (7%) tumours had
strong EGFR signals and 8 (6%) had weak immunoreactivity.
HER2 expression. Only 3 of 140 PETs (2%) stained for HER2
(Figure 1C). Among these, one tumour had a strong
membranous signal and two displayed weak and focal
immunoreactivity.
KIT expression. Sixteen of 140 PETs (11%) showed KIT
immunostaining. A prevalently membranous staining was
detected in seven tumours (5%) with variable intensity (six
strong and one weak) (Figure 1A). Nine cases showed
cytoplasmic staining alone, of these one had strong intensity
and ﬁve showed a dot-like positivity. Among the cases
displaying dot-like positive staining, there was the tumour
bearing the mutated KIT gene (Table 2). This is somewhat
expected since the dot-like KIT immunostaining pattern is
Table 2. Mutations indentiﬁed in protein kinase genes
Gene Nucleotide
change
Amino acid
change
Mutation type Zygosity Sample Cross-reference
annotation
b
ATM c.2879 C>T p.R823C Missense Heterozygous 528 n.f.
ATM c.6435 G>T p.S2017I Missense Heterozygous. 502 n.f.
FGFR3 c.1003 G>A p.E322K Missense Heterozygous QGP
a Variant in cancer
FLT1 c.2594 G>A p.R781Q Missense Heterozygous CM
a Variant in cancer
KIT c.2386 A>T p.R796stop Nonsense Heterozygous 365 n.f.
PI3KCA c.1790 A>C p.E545A Missense Heterozygous BON
a Variant in cancer
The mutations are listed by gene alongside the samples in which they were found. The nucleotide numbering uses the A of the ATG translation initiation start
site as nucleotide + 1, based on reference sequences provided in supplemental Table S2 (available at Annals of Oncology online).
aPET cell lines. QGP, established from a non-functioning islet cell tumor; CM, established from ascitic ﬂuid of an insulinoma; BON, established from
a metastasis of a pancreatic carcinoid tumor.
bThe genetic alteration identiﬁed were cross-referenced with variant information from databases and literature.
c., cDNA sequence; n.f., alterations not previously found in cancer; p., protein sequence; stop, stop codon.
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PET immunopositive cases were sequenced for KIT gene
revealing no genetic abnormalities.
PDGFRalpha expression. Cytoplasmic staining was found in
135 of 140 (96%); the remaining 5 cases (4%) were negative.
Nuclearimmunostainingwaspresentin129andabsentin6cases
(5%). Cell membranes were always negative, while the stromal
component stained in all 140 cases (Figure 1D).
FISH analysis
FISH analysis for EGFR and HER2 was carried out on the same
TMAs used for immunohistochemical analysis. Ten of the 140
PETs (7%) were not informative for both EGFR and HER2
analysis. Figure 2 shows examples of ﬂuorescent hybridisation.
No differences were observed between primary tumours and
matched metastases for both EGFR and HER2.
EGFR. No case had gene ampliﬁcation; 86 of 130 PETs (66%)
were disomic, 27 (21%) were polysomic–trisomic and 17 (13%)
were monosomic (Figure 2A).
HER2. Gene ampliﬁcation was observed in 2 of 130 (1.5%)
cases (Figure 2B): one in a tumour showing strong protein
immunostaining and the second in a tumour displaying
negative immunoreactivity. Of the 130 informative PETs, 108
(83%) were disomic, 15 (11%) polysomic–trisomic and 7 (5%)
monosomic.
correlation of RTK gene status and protein
expression with clinical pathological information
Immunohistochemical and FISH results were correlated with
clinicopathological features. At univariate analysis, an
Table 3. Expression of receptor tyrosine kinases in pancreatic endocrine tumours (PETs)
EGFR HER2 KIT
a PDGFRalpha
b
Tumour Stroma
Total number of PETs 18/140 (13%) 3/140 (2%) 16/140 (11%) 135/135 (100%) 135/135 (100%)
Nonfunctioning 17/106 (16%) 3/106 (3%) 12/106 (11%) 103/103 (100%) 103/103 (100%)
Functioning 1/34 (3%) 0/34 (–) 4/34 (12%) 32/32 (100%) 32/32 (100%)
EGFR, epidermal growth factor receptors; HER2, human epidermal growth factor receptor 2; KIT, tyrosine-protein kinase KIT; PDGFRalpha, platelet-
derived growth factor alpha.
aPositive immunostaining refers to the detection of both membranous and cytoplasmic signals.
bFive cases were not evaluable; positive immunostaining refers to the detection of cytoplasmic signals.
Figure 1. Immunohistochemical staining for receptor tyrosine kinases in
pancreatic endocrine tumours. Shown are positive staining for KIT (A),
EGFR (B) and HER2 (C) in tumour cells; positive staining in tumour cells
and in the stroma is shown for PDGFRalpha (D). Original magniﬁcation,
x20.
Figure 2. Fluorescent in situ hybridisation (FISH) analysis for EGFR and
HER2 in pancreatic endocrine tumours. FISH analysis showing monosomy
for EGFR (A), and gene ampliﬁcation for HER2 (B). Original
magniﬁcation, ·100. EGFR and HER2 signal red, centromeric probes
signal green.
original articles Annals of Oncology
130 | Corbo et al. Volume 23| No. 1| January 2012association was found between immunohistochemical KIT
membrane positivity and tumour aggressiveness (Table 4). In
fact, a positive staining signiﬁcantly correlated with a diagnosis
of carcinoma either well or poorly differentiated (P < 0.001),
with liver and lymph node metastasis at diagnosis (P < 0.001),
vascular (P = 0.004) and neural (P = 0.005) invasion and a Ki67
index >5% (P = 0.015). Moreover, a signiﬁcant association was
found between HER2 disomic status at FISH and benign
tumours (P = 0.004). Conversely, no association was found
between mutational data and either clinicopathological data or
protein expression and FISH data.
By Mann–Whitney test, no difference was found between
primary tumours and metastases for both receptor expression
and FISH data.
By Kaplan– Meier analysis, a signiﬁcant association was
found between KIT membrane immunostaining and survival
(P < 0.001) (Figure 3).
discussion
The need for effective systemic treatment options for patients
with PET led us to explore the kinome searching for candidate
targets of anticancer drugs.
We ﬁrst operated a mutational survey of 35 kinase genes in
36 primary PETs and 3 PET cell lines that showed (i) no
mutations in AKT2, PIK3CA, RPS6K1, STK11, PDPK1, and
FRAP1-mTOR, which are six key genes of the Akt/mTOR
pathway; (ii) among the four genes encoding for RTKs targeted
by exiting drugs, no mutation was found in EGFR, HER2, and
PDGFRalpha, while KIT was mutated in one case; (iii)
mutations in ATM in two different cases were the only
alterations affecting the remaining 25 screened genes; (iv) the
cell lines QGP1, CM and BON, which represent the most
extensively used cellular models for functional and preclinical
studies concerning PETs, displayed mutations of kinase
genes that are amenable of therapeutic targeting that are
FGFR3, FLT1/VEGFR1 and PIK3CA, respectively. We then
carried out an immunohistochemical survey of the four
targetable RTKs in 140 primary PETs showing that (i) EGFR
was expressed in 13% of cases, (ii) HER2 in 2% and (iii) KIT
in 11%, whereas (iv) PDGFRalpha immunostaining was
found in all cases. FISH analysis on 130 PETs showed no
gene ampliﬁcation for EGFR, whereas two PETs harboured
ampliﬁed HER2 genes.
This study involved the largest panel of primary PETs that
has been ever screened for somatic mutations of kinase genes
and led to the identiﬁcation of a total of six different
nonsynonymous mutations affecting ﬁve kinase genes (FGFR3,
FLT1/VEGFR1, PIK3CA, ATM and KIT).
The mutations found in FGFR3 (p.E322K), FLT1/VEGFR1
(p.R781Q) and in PIK3CA (p.E545A) were identiﬁed in
established cell lines and all have been previously related to
human cancers [44–50].
The remaining three mutations were found in three different
primary tumours and were somatic in origin as assessed by
sequencing of their matched normal DNA. None of these
mutations were previously described in cancers. Two
neoplasms that had previously been shown to lack MEN1
Table 4. Correlation of KIT membrane expression with
clinicopathological parameters
Parameter n KIT-positive tumours P
a
WHO classiﬁcation 140
WDET 76 0
WDEC 59 4
PDEC 5 3 <0.001
Functional status 140
F-PET 34 0
NF-PET 106 7 0.19
Proliferation index 138
Ki67 £5% 101 2
Ki67 >5% 37 5 0.015
Liver metastases 140
Absent 110 1
Present 30 6 < 0.001
Lymph node metastases 140
Absent 98 0
Present 42 7 < 0.001
Vascular invasion 136
Absent 73 0
Present 63 7 0.004
Neural invasion 136
Absent 91 1
Present 45 6 < 0.005
aFisher’s exact test.
WDET, well-differentiated endocrine tumours; WDEC, well-differentiated
endocrine carcinoma; PDEC, poorly differentiated endocrine carcinoma;
F, functioning; NF, nonfunctioning.
Figure 3. Correlation between KIT membrane immunostaining and
patients’ survival. Kaplan–Meier estimates of survival with regard to KIT
membrane immunostaining (P < 0.001). Follow-up, months; KIT+,
membrane-positive immunostaining; KIT2, membrane-negative
immunostaining.
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both ATM and MEN1 map to chromosomal arm 11q, which is
frequently lost in PET [52]. The ﬁnding of ATM mutations
could partially address the observed discrepancy between the
rate of 11q deletion and the lower frequency of MEN1
mutations in PET [51, 52]. Our mutational screening also
revealed a nonsense mutation affecting the catalytic domain of
KIT that requires further experimental evaluation to assess its
functional signiﬁcance. KIT mutational activation is a feature of
gastrointestinal stromal tumours [53, 54] and represents
a therapeutic target for this malignancy [55]. The role of KIT in
PET is still unknown although imatinib mesylate showed
a cytotoxic effect on BON cell line [56].
Increasing evidence suggests that the development of efﬁcient
therapeutic strategies for cancer treatment implies the
recognition of altered pathways rather than their individual
components [57]. Regarding PETs, especially the signiﬁcance
of Akt-mTOR pathway and its therapeutic relevance have
been addressed by different groups, including ours [13–17].
In this study, we analysed the mutational proﬁles of six
kinases related to the Akt-mTOR pathway: AKT2, PIK3CA,
RPS6K1, STK11, PDPK1 and FRAP1/mTOR.N op r i m a r y
tumour harboured mutations in these genes, whereas BON
cell line displayed an activating mutation of PIK3CA.
Established from a metastatic pancreatic ‘carcinoid’ tumour,
BON represents the most extensively used model system for
the study of PETs and was previously demonstrated to exhibit
a constitutive Akt/mTOR activation supposedly due to an
autocrine IGF-I loop [58]. QGP1 cell line, derived from
a primary pancreatic functioning tumour, contains
am u t a t i o ni nVEGFR1. Therefore, our characterisation of
established cell lines with the regard to alterations in kinase
genes ﬁnally provides suitable model systems for preclinical
study, particularly in the light of the recent interest for the
development of new drugs targeting mTOR/PIK3CA as well
as VEGFR activity [59].
The rationale for targeting RTKs resides not only in the
identiﬁcation of gene mutations but also in the determination
of their status at both the protein and gene level [22–26]. In line
with this, we assessed the protein expression of EGFR, HER2,
KIT and PDGFRalpha by immunohistochemistry and gene
copy number status of EGFR and HER2 in 140 primary PETs,
which included the 36 PETs screened for kinase genes
mutations.
The most relevant ﬁnding of this analysis regards the
expression of KIT. Indeed, 16 of 140 (11%) cases displayed
staining for KIT, 7 (5%) of which showed a prevalent
membranous signal. This latter feature showed a signiﬁcant
association with tumour aggressiveness and patients’ shorter
survival at univariate analysis (P < 0.001), which was not
retained at multivariate analysis. This result differs from that
by Zhang et al. [33] who reported that KIT expression was an
independent prognostic factor. Concerning EGFR and HER2,
neoplastic cells stained for EGFR in 13% (18/140) and for
HER2 in 2% (3/140) of samples. No gene ampliﬁcation was
observed for EGFR, whereas two cases showed a high-level
HER2 gene ampliﬁcation; of these only one expressing the
protein. Immunostaining for PDGFRalpha was found in both
stroma and neoplastic cells of all cases.
The expression of RTKs had already been investigated in
PETs (Table 5), with overlapping results for HER2 and
PDGFRalpha in our series [28, 30, 34, 35]. For KIT
immunostaining, our data are not dissimilar from those
obtained by Zhang et al. [33] using the same antibody, while
our ﬁgure for EGFR immunostaining is deﬁnitely lower than
that reported by others [27, 29–32]. However, our EGFR
Table 5. Expression of receptor tyrosine kinases in published series of pancreatic endocrine tumours
Antigen and reference PET cases,
a positive/total (%) Antibody information
b
EGFR
Fja ¨llskog et al. [30] 21/38 (55) Santa Cruz (San Francisco, CA)
Papouchado et al. [29] 12/48 (25) Santa Cruz
Bergmann et al. [31] 30/65 (46) Zymed-Invitrogen (Carlsband, CA)
Peghini et al. [27] 6/15 (40)
c Santa Cruz
Srivastava et al. [32] 23/35 (65)
d Zymed and Oncogene (San Diego, CA)
HER2
Proca et al. [28] 0/27 Dako (Carpinteria, CA)
Goebel et al. [34] 0/10
c Dako
KIT
Fja ¨llskog et al. [30] 35/38 (92) Santa Cruz
Zhang et al. [33] 21/97 (22) Dako
PDGFRalpha Tumour Stroma
Fja ¨llskog et al. [30] 38/38 21/37 (57%) Santa Cruz
Chaudhry et al. [35] 4/5 5/5 In-house
e
aExcept for PDGFRalpha, only the staining of neoplastic cells from primary tumours was considered.
bManufacturers.
cThese tumours were all gastrinomas.
dThe overall frequency of EGFR expression refers to the positive immunostaining with either antibodies as reported in this study
eFor information about PDGFRalpha antibody refers to Eriksson et al. [60]
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DakoCytomation EGFR pharmDx .
In conclusion, in this study we report six different
mutations affecting ﬁve kinase genes in PET. The ﬁnding of
speciﬁc mutations in the few available PET cell lines renders
these models useful for preclinical studies involving pathway-
speciﬁc therapies. None of the alterations identiﬁed in
primary tumours were previously related to cancer. Those
affecting ATM were found among cases lacking MEN1
mutations, thus possibly explaining the observed differences
between the rate of chromosome 11q allelic losses and that of
MEN1 mutations. KIT membrane expression seems to be
a prognostic marker deserving further attention. Although
PET lacked activating mutations in most of the screened genes,
we showed that rare cases, namely those harbouring either
HER2 ampliﬁcation or KIT mutation, might beneﬁt from
available targeted drugs.
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